Cumberland Pharmaceuticals (NASDAQ:CPIX) Receives New Coverage from Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a research report issued on Thursday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Stock Up 4.1 %

Shares of Cumberland Pharmaceuticals stock opened at $1.52 on Thursday. The firm’s 50 day moving average price is $1.55 and its 200-day moving average price is $1.78. The company has a quick ratio of 1.21, a current ratio of 1.37 and a debt-to-equity ratio of 0.59. Cumberland Pharmaceuticals has a 52-week low of $1.38 and a 52-week high of $2.36. The company has a market cap of $21.57 million, a P/E ratio of -2.58 and a beta of 0.23.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its quarterly earnings data on Tuesday, May 7th. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter. Cumberland Pharmaceuticals had a positive return on equity of 0.21% and a negative net margin of 21.67%. The firm had revenue of $8.50 million during the quarter.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.